Chennai-based, export-led manufacturer of non-betalactum solid oral dosage forms (tablets, capsules) for regulated and emerging pharma markets, also acting as a Contract Manufacturing Organization (CMO/CRAMS partner).
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY13 | FY14 | FY15 | FY16 | FY17 | FY18 | FY19 | FY20 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 19 | 19 | 19 | 19 | 19 | 24 | 24 | 2 |
| Reserves | 49 | 50 | 53 | 39 | 24 | 14 | -5 | 49 |
| Borrowings | 100 | 108 | 69 | 80 | 82 | 47 | 46 | 3 |
| Other Liabilities | 93 | 59 | 59 | 54 | 53 | 54 | 54 | 17 |
| Total Liabilities | 261 | 236 | 200 | 193 | 178 | 138 | 119 | 71 |
| AssetsFixed Assets | 73 | 69 | 55 | 53 | 49 | 45 | 37 | 35 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 17 | 17 | 17 | 0 | 0 | 0 |
| Other Assets | 188 | 167 | 128 | 123 | 113 | 93 | 82 | 36 |
| Total Assets | 261 | 236 | 200 | 193 | 178 | 138 | 119 | 71 |
| Line item | FY13 | FY14 | FY15 | FY16 | FY17 | FY18 | FY19 | FY20 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 37 | 2 | 11 | 1 | -1 | -7 | -2 | -34 |
| Cash from Investing | -6 | -7 | 60 | 0 | -5 | 38 | 15 | 33 |
| Cash from Financing | -12 | -13 | -71 | -1 | 6 | -31 | -14 | 7 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 34 | 0 | 44 | -1 | -1 | 40 | 3 | -36 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
BAFNAPH · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.